Isolation and identification of SARS-CoV-2 antibodies from COVID-19 patient samples

Isolation and identification of SARS-CoV-2 antibodies from COVID-19 patient samples

<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causing agent for COVID-19, has led to over 7 million deaths since it was first detected in Wuhan, China in December 2019. Antibodies induced by both vaccination and infection are crucial for the immune protection ag...

Bibliografske podrobnosti
Glavni avtor:	Liu, C
Drugi avtorji:	Screaton, GR
Format:	Thesis
Jezik:	English
Izdano:	2024
Teme:	Immunology

Podobne knjige/članki

SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
od: Alba Escalera, et al.
Izdano: (2024-03-01)

Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection
od: Xiao-Lin Jiang, et al.
Izdano: (2024-07-01)

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2
od: Cyril Planchais, et al.
Izdano: (2024-07-01)

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
od: Jeewandara, C, et al.
Izdano: (2021)

Cross-reactive immunity to SARS-CoV-2 and related coronaviruses
od: Jay, C
Izdano: (2023)

Nonhuman primate antigenic cartography of SARS-CoV-2
od: Annika Rössler, et al.
Izdano: (2025-01-01)

Studies on immunoreceptor activation and SARS-CoV-2 RBD/ACE2 interactions
od: Barton, MI
Izdano: (2022)

Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets
od: Kiira Gildemann, et al.
Izdano: (2024-07-01)

SARS-CoV-2 produces a microRNA CoV2-miR-O8 in patients with COVID-19 infection
od: Elise J. Tucker, et al.
Izdano: (2024-01-01)

Epitopes recognition of SARS-CoV-2 nucleocapsid RNA binding domain by human monoclonal antibodies
od: Youngchang Kim, et al.
Izdano: (2024-02-01)

Development of human monoclonal antibodies against SARS-CoV-2
od: Wong, Joel Xu En
Izdano: (2021)

SARS-CoV-2 infection elucidates features of pregnancy-specific immunity
od: Dong Sun Oh, et al.
Izdano: (2024-11-01)

Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination
od: Miroslava Cuperlovic-Culf, et al.
Izdano: (2024-08-01)

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
od: Tetsuya Inoue, et al.
Izdano: (2024-04-01)

Increasing Sporadic Covid-19 Cases:Should We Heed Airborne Transmission Of SARS-CoV-2?
od: Ahmad Mahfuz, Gazali
Izdano: (2021)

An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike
od: Banghui Liu, et al.
Izdano: (2024-06-01)

Characterisation of HBV and SARS-CoV-2 spike specific T cells and their association with viral control
od: Liu, G
Izdano: (2023)

Functional diversification of innate and inflammatory immune responses mediated by antibody fragment crystallizable activities against SARS-CoV-2
od: Martina Severa, et al.
Izdano: (2024-05-01)

SARS-CoV-2 vaccine development and challenges
od: Duan Fugang, et al.
Izdano: (2021-03-01)

Elucidating factors of heterogeneous immune response to SARS-CoV-2 and human immunodeficiency virus
od: Lim, N
Izdano: (2024)

Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1
od: Zhou Tong, et al.
Izdano: (2024-06-01)

SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
od: Elizabeth J. Martinez, et al.
Izdano: (2024-10-01)

Variant- and vaccination-specific alternative splicing profiles in SARS-CoV-2 infections
od: Sung-Gwon Lee, et al.
Izdano: (2024-03-01)

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
od: Cara W. Chao, et al.
Izdano: (2024-12-01)

SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model
od: Sarah E. Cummings, et al.
Izdano: (2024-01-01)

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
od: Carter, Brandon, et al.
Izdano: (2023)

tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains
od: Daniel Ivanusic, et al.
Izdano: (2024-03-01)

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1
od: Alexander Muik, et al.
Izdano: (2024-08-01)

Convergence of SARS-CoV-2 spike antibody levels to a population immune setpointResearch in context
od: Eric J. Nilles, et al.
Izdano: (2024-10-01)

Characterising the T cell responses to SARS-CoV-2 including variants of concern induced by natural infection and vaccines
od: Adele, S
Izdano: (2024)

Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters
od: Rajesh Rajaiah, et al.
Izdano: (2024-08-01)

Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion
od: Lu Zhang, et al.
Izdano: (2024-06-01)

Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection
od: Mohamed I.M. Ahmed, et al.
Izdano: (2024-06-01)

Immune imprinting of SARS-CoV-2 responses: changing first immune impressions
od: J. Torresi, et al.
Izdano: (2024-04-01)

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine
od: Masayuki Aboshi, et al.
Izdano: (2024-02-01)

A systems biology approach to define SARS-CoV-2 correlates of protection in non-human primates
od: Brady, C
Izdano: (2024)

The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection
od: Hui Wang, et al.
Izdano: (2024-06-01)

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
od: Willett, BJ, et al.
Izdano: (2022)

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
od: Hirsch, C, et al.
Izdano: (2021)

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
od: Kreuzberger, N, et al.
Izdano: (2021)